Vildagliptin is a potent and selective inhibitor of Dipeptidyl Peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (α and β) islet function. Vildagliptin reduces HbA1c when given as monotherapy, without weight gain and with minimal hypoglycemia, or in combination with the most commonly prescribed classes of oral hypoglycemic drugs. In this study comparison of efficacy and safety of vildagliptin versus Glimepiride and Metformin in Type 2 Diabetes mellitus were carried out. Plasma glucose levels were measured at baseline and study end point (12 weeks) in a trial evaluating add-on therapy to metformin with 50 mg vildagliptin od and Glimepiride up to 4 mg compared with Glimepiride up to 6 mg in Type 2 Diabetes. Glycosylated haemoglobin (A1C), Fasting Plasma Glucose (FPG) and Post prandial glucose (PPG) were reduced similarly in both groups. Hypoglycaemic events were less in both the groups. Combination of Vildagliptin to Glimepiride and metformin therapy improved A1C, fasting and postprandial glucose levels without hypoglycaemia.
Loading....